Seeking Alpha

Furiex Pharmaceuticals, Inc. (FURX)

FURX is defunct.
  • Apr. 28, 2014, 8:27 AM
    • Forest Labs (FRX) acquires Furiex Pharmaceuticals (FURX) for $95/share ($1.1B) in cash and up to $30/share in a Contingent Value Right (CVR) payable on the regulatory approval of eluxadoline.
    • Forest will divest Furiex's royalties on alogliptin and Priligy to Royalty Pharma for $415M which will reduce its purchase price by ~$315M (after tax).
    • Furiex shares are up 26% premarket on robust volume.
    | Apr. 28, 2014, 8:27 AM | Comment!
  • Feb. 19, 2014, 12:11 PM
    • Bloomberg reports Furiex Pharma (FURX +6.5%) has hired BofA/Merrill to help find a buyer. Shares have spiked higher in response.
    • Two weeks ago, Furiex more than doubled in response to news its Eluxadoline irritable bowel syndrome drug had met the company's main objectives in a late-stage study.
    | Feb. 19, 2014, 12:11 PM | Comment!
Company Description
Furiex Pharmaceuticals, Inc. is a drug development collaborate company that collaborates with pharmaceutical and biotechnology companies to increase the value of their drug candidates by applying an accelerated approach to drug development.